Close Menu
NERDBOT
    Facebook X (Twitter) Instagram YouTube
    Subscribe
    NERDBOT
    • News
      • Reviews
    • Movies & TV
    • Comics
    • Gaming
    • Collectibles
    • Science & Tech
    • Culture
    • Nerd Voices
    • About Us
      • Join the Team at Nerdbot
    NERDBOT
    Home»News»FDA Approves First New Alzheimer’s Drug in 20 Years
    Photo by Andrea Piacquadio from Pexels
    News

    FDA Approves First New Alzheimer’s Drug in 20 Years

    Breana CeballosBy Breana CeballosJune 7, 20213 Mins Read
    Share
    Facebook Twitter Pinterest Reddit WhatsApp Email

    Aducanumab is going to be the thing most everyone is talking about. It’s a new drug that has been approved by the Food and Drug Administration to treat early signs of Alzheimer’s. The problem with it however that it was approved despite there being evidence that the pros outweigh the cons. And the FDA advisory committee said that it also lacked evidence that it would be effective in treating the disease at all. The reason that’s its noteworthy that this drug was approved is because the FDA has not approved a new drug for treatment in over 20 years.

    This new drug, aducanumab, was created to treat the early symptoms and ease progression of Alzheimer’s. It’s not for people with advanced Alzheimer’s or dementia.

    In response to a question about whether it was reasonable to consider data from one positive study as the primary evidence of aducanumab’s effectiveness for the treatment of early Alzheimer’s disease, none of the committee members voted yes — 10 voted no and one was uncertain.

    ABC7 News

    Administered intravenously, the drug was created by pharmaceutical company Biogen, and its Japanese partner, Eisai. Dr. Richard Isaacson, director of the Alzheimer’s Prevention Clinic at Weill Cornell Medicine and NewYork-Presbyterian in New York was part of the initial study. He had patients try the new drug and says that “we really have to temper our expectations.”

    “This drug targets the earliest symptomatic phase of the disease, called mild cognitive impairment due to Alzheimer’s. Treatment of this pre-dementia period is what the FDA is deciding on”

    “We have to really temper expectations and explain to people that this drug is meant for the earliest symptomatic phases. It pains me to say this but if I have a severe Alzheimer’s patient that can no longer speak or interact much with others and their family member is begging me to give them this drug, I won’t be able to do it.”

    Dr. Richard Isaacson
    Photo by Andrea Piacquadio from Pexels

    It’s Expensive and It Might Not Work

    Along with not enough evidence to support that it’s more helpful than harmful there is also a large price tag to even try this out. In May, the Institute for Clinical and Economic Review put out a draft report guessing that the drug should cost between $2,560 to $8,290 per year. That’s a lot of money for something that might not work.

    It wasn’t until a study run by Biogen, one of the companies that manufactures the drug was put out. With the numbers released from the new study it was found that with a very high dose of the drug it stalled the progression of Alzheimer’s.

    The company noted in FDA briefing documents last year that patients treated with high-dose aducanumab showed 22% less clinical decline in their cognitive health at about 18 months — meaning the progression of their early Alzheimer’s disease slowed — compared with those who received a placebo

    ABC7

    Do You Want to Know More?

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email
    Previous ArticleBrood X is on the Move: Cicada Swarm Ping Weather Systems
    Next Article Rap Snacks: Chips and Ramen Celebrating Rap Icons [Food Review]
    Breana Ceballos
    • Website

    Anime enthusiast, Hearthstone Battleground addict.

    Related Posts

    GWAR’s Blothar Attacks Bill Cutting Funding to PBS, NPR

    July 19, 2025

    WGA Condemns CBS Cancelling “The Late Show,” Colbert

    July 18, 2025

    Coldplay Kiss Cam Moment Becomes Etsy Treasure Trove

    July 18, 2025

    “I Know What You Did Last Summer” Pretty Cast, Same Bland Story [Review]

    July 17, 2025

    Dinosaur Fossil Sells for Over $30 Million at Auction

    July 17, 2025

    “Cloud” Internet Anonymity is the Gateway to Hell [Review]

    July 16, 2025
    • Latest
    • News
    • Movies
    • TV
    • Reviews

    Tips and tools to help you pass exams

    July 20, 2025

    Why Clothing Brands Are Switching from DTG to DTF in 2025

    July 20, 2025

    What Is a DTF Gang Sheet Builder? And Why Creators Love It

    July 20, 2025

    How DTF Printing Is Disrupting the Custom Apparel Industry in 2025

    July 20, 2025

    GWAR’s Blothar Attacks Bill Cutting Funding to PBS, NPR

    July 19, 2025

    WGA Condemns CBS Cancelling “The Late Show,” Colbert

    July 18, 2025

    Coldplay Kiss Cam Moment Becomes Etsy Treasure Trove

    July 18, 2025

    “I Know What You Did Last Summer” Pretty Cast, Same Bland Story [Review]

    July 17, 2025

    Cameras are Rolling on “Practical Magic 2!”

    July 18, 2025

    “I Know What You Did Last Summer” Pretty Cast, Same Bland Story [Review]

    July 17, 2025

    Taika Waititi, Drew Pearce to Tackle “Judge Dredd”

    July 17, 2025

    NEW Official Trailer for “Tron: Ares” Hits

    July 17, 2025
    "South Park"

    Isaac Hayes III Says ‘Dad Would Never Quit’ “South Park”

    July 19, 2025
    "Alien: Earth"

    Noah Hawley’s “Alien: Earth” Gets a Brand New Trailer

    July 18, 2025

    CBS Announces the End of “The Late Show” in 2026

    July 17, 2025

    Berlanti Developing Live-Action “Captain Planet’ Series for Netflix

    July 17, 2025

    “I Know What You Did Last Summer” Pretty Cast, Same Bland Story [Review]

    July 17, 2025

    “Cloud” Internet Anonymity is the Gateway to Hell [Review]

    July 16, 2025

    “Life After” Impartial Exposé on Complex, Important Issues [Review]

    July 15, 2025

    “Superman” Big, Beautiful Mess Bursting With Color, Hope [Review]

    July 11, 2025
    Check Out Our Latest
      • Product Reviews
      • Reviews
      • SDCC 2021
      • SDCC 2022
    Related Posts

    None found

    NERDBOT
    Facebook X (Twitter) Instagram YouTube
    Nerdbot is owned and operated by Nerds! If you have an idea for a story or a cool project send us a holler on [email protected]

    Type above and press Enter to search. Press Esc to cancel.